We recently published a list of 11 Stocks with Consistent Growth to Buy Now. In this article, we are going to take a look at where Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) stands against stocks with consistent growth to buy now.

The market is clouded by friction between trading partners. But even at these uncertain times, one investment strategy remains remarkably consistent: betting on growth.

Investors are consistently drawn toward companies that have demonstrated a solid long-term expansion in revenue and earnings. The mechanism behind this is simple: stocks with stable growth offer the potential for compounding returns over time in low-rate environments. Lately, however, the stocks have done more than just show potential. They are leading the market.

READ ALSO: 10 Dividend Paying Stocks Insiders Are Buying and 20 Takeover Rumors Hedge Funds Are Buying.

On April 22, 2025, the market indices surged by 2.5%, contributed by renewed confidence in the ability of high-growth equities to endure the market uncertainty. As per a report from CNBC, confidence emerged after the de-escalation of tensions in U.S. monetary policy.

Recent political developments have detoured the market sentiment towards further interest rate cuts by the Federal Reserve. President Trump has backed off from his threats towards the Fed Chair Jerome Powell. However, he firmly believes that the Fed should be more aggressive in lowering interest rates. When this belief was put in words, an immediate surge was noticed in the equity index futures, suggesting the high sensitivity of the market policy cues, particularly when it comes to growth potential.

Investors took the cue seriously, pricing in three interest rate cuts by the end of 2025. For growth-oriented companies, the lower borrowing costs can be favorable, specifically if they are in their early to mid-stages of expansion, since capital costs can be reduced and earnings multiples can be improved. Also, with inflationary pressures still in check and the global economic activity indicating resilience, the macroeconomic environment favors growth investing. It shows that the current climate supports equities positioned for sustained performance instead of short-term valuation plays.

Not just today, but growth stocks have historically proven their worth in the market for over three decades. These stocks have surpassed their value counterparts in performance, even after considering the major downturns.

During economic volatility or even political flux, investors seek clarity. And the provider of such clarity or edge is the growth equities. These companies often reinvest profits and innovate rapidly to achieve more market share. Though they may not always deliver dividends, they reward investors through capital appreciation. During the recovery phases, investors desire such appreciation, which comes in addition to the safety of the investment. As CNBC’s recent coverage notes, recoveries are initiated in the form of bear market rallies, and the investors capable of identifying early movers in such cycles typically come out ahead.

That said, selectivity is the key. Investors must understand that not all growth is created equal. Every rally does not signal a lasting trend. And it is here that our article gains its value. We have identified 11 stocks that have consistently delivered. It is not just the quarterly earnings or media buzz we focused on, but also the years of disciplined execution and strategic expansion.

So, if you are looking for clarity amid the noise, you are in the right place.

Our Methodology

We followed a few criteria when compiling our list of 11 stocks with consistent growth that investors may want to buy. Primarily, we looked into the growth of each stock for the past five years. We did not include any stock with negative growth. Additionally, we narrowed our picks by selecting only those stocks that have been consistently growing throughout the past 5 years. This ensures that all our picks have solid historical data to support capital appreciation further into the future. Finally, we ranked our picks using the stocks’ average growth rate in returns in the past five years. All the data used in this article were taken from financial news, databases, and analyst reports, with all information updated as of April 23, 2025.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

5-Year Average Growth Rate: 75.17%

No. of Hedge Funds: 35

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), a Florida-based company, is developing therapies for rare neurological diseases. The company takes pride in its lead product, Firdapse®, which treats Lambert-Eaton myasthenic syndrome (LEMS) with limited treatment options. Competing with other rare disease firms, it uses lifecycle management strategies, orphan drug exclusivity, and selective in-licensing of pipeline assets to gain a competitive advantage. In particular, focusing on neuromuscular disorders enables the company to deliver sustained growth within underserved patient populations. It is one of the best stocks with consistent growth.

Strategic drug development alongside niche targeting has helped achieve a 75.17% growth average rate in the past 5-year period. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has reported a record total revenue of $141.8 million in the fourth quarter of 2024, a 28.3% increase compared to the same period in the prior year. Firdapse and Agamree heavily contributed to this revenue growth. With continued growth in these two products, the company anticipates a total revenue between $545 million and $565 million for 2025. Additionally, having completed 2024 with no debt and a massive cash position of $517.6 million, the company has expanded its capacity to invest in strategic growth opportunities.

Currently backed by 35 hedge funds, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) represents a mid-cap biotech with long-term consistent growth that may interest investors focusing on high-growth pharmaceutical stocks.

Overall, CPRX ranks 8th on our list of stocks with consistent growth to buy now. While we acknowledge the potential of CPRX, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than CPRX but trades at less than 5 times its earnings check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.